146 related articles for article (PubMed ID: 7933839)
1. Receptor binding and degradation of urokinase-type plasminogen activator by human mesangial cells.
Nguyen G; Li XM; Peraldi MN; Zacharias U; Hagège J; Rondeau E; Sraer JD
Kidney Int; 1994 Jul; 46(1):208-15. PubMed ID: 7933839
[TBL] [Abstract][Full Text] [Related]
2. Regulation of the urokinase-type plasminogen activator receptor on vascular smooth muscle cells is under the control of thrombin and other mitogens.
Reuning U; Bang NU
Arterioscler Thromb; 1992 Oct; 12(10):1161-70. PubMed ID: 1327097
[TBL] [Abstract][Full Text] [Related]
3. Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells.
Grimsley PG; Normyle JF; Brandt RA; Joulianos G; Chesterman CN; Hogg PJ; Owensby DA
Thromb Res; 1995 Aug; 79(4):353-61. PubMed ID: 7482438
[TBL] [Abstract][Full Text] [Related]
4. Urokinase synthesis and binding by glomerular epithelial cells in culture.
Rondeau E; Ochi S; Lacave R; He CJ; Medcalf R; Delarue F; Sraer JD
Kidney Int; 1989 Oct; 36(4):593-600. PubMed ID: 2554052
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
Lijnen HR; De Cock F; Collen D
Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
[TBL] [Abstract][Full Text] [Related]
6. Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
Barnathan ES; Kuo A; Rosenfeld L; Karikó K; Leski M; Robbiati F; Nolli ML; Henkin J; Cines DB
J Biol Chem; 1990 Feb; 265(5):2865-72. PubMed ID: 2154462
[TBL] [Abstract][Full Text] [Related]
7. Two-chain urokinase, receptor, and type 1 inhibitor in cultured human mesangial cells.
Glass WF; Kreisberg JI; Troyer DA
Am J Physiol; 1993 Mar; 264(3 Pt 2):F532-9. PubMed ID: 8384415
[TBL] [Abstract][Full Text] [Related]
8. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen.
Nguyen G; Delarue F; Berrou J; Rondeau E; Sraer JD
Kidney Int; 1996 Dec; 50(6):1897-903. PubMed ID: 8943472
[TBL] [Abstract][Full Text] [Related]
9. Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells.
Jensen PH; Christensen EI; Ebbesen P; Gliemann J; Andreasen PA
Cell Regul; 1990 Dec; 1(13):1043-56. PubMed ID: 1966892
[TBL] [Abstract][Full Text] [Related]
10. Urokinase binding and receptor identification in cultured endothelial cells.
Haddock RC; Spell ML; Baker CD; Grammer JR; Parks JM; Speidel M; Booyse FM
J Biol Chem; 1991 Nov; 266(32):21466-73. PubMed ID: 1657968
[TBL] [Abstract][Full Text] [Related]
11. Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.
Morton PA; Owensby DA; Sobel BE; Schwartz AL
J Biol Chem; 1989 May; 264(13):7228-35. PubMed ID: 2540181
[TBL] [Abstract][Full Text] [Related]
12. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
Sitter T; Toet K; Quax P; Kooistra T
Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase.
Hajjar KA; Hamel NM
J Biol Chem; 1990 Feb; 265(5):2908-16. PubMed ID: 2154465
[TBL] [Abstract][Full Text] [Related]
14. Induction of c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells.
Dumler I; Petri T; Schleuning WD
FEBS Lett; 1994 Apr; 343(2):103-6. PubMed ID: 8168613
[TBL] [Abstract][Full Text] [Related]
15. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade.
Baricos WH; Cortez SL; el-Dahr SS; Schnaper HW
Kidney Int; 1995 Apr; 47(4):1039-47. PubMed ID: 7540230
[TBL] [Abstract][Full Text] [Related]
16. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism.
Schwartz BS
J Biol Chem; 1994 Mar; 269(11):8319-23. PubMed ID: 7907591
[TBL] [Abstract][Full Text] [Related]
17. Identification and partial characterization by chemical cross-linking of a binding protein for tissue-type plasminogen activator (t-PA) on rat hepatoma cells. A plasminogen activator inhibitor type 1-independent t-PA receptor.
Bu G; Morton PA; Schwartz AL
J Biol Chem; 1992 Aug; 267(22):15595-602. PubMed ID: 1322401
[TBL] [Abstract][Full Text] [Related]
18. Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor and surface expression of the u-PA receptor.
Casslén B; Nordengren J; Gustavsson B; Nilbert M; Lund LR
J Clin Endocrinol Metab; 1995 Sep; 80(9):2776-84. PubMed ID: 7673423
[TBL] [Abstract][Full Text] [Related]
19. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification.
Nielsen LS; Kellerman GM; Behrendt N; Picone R; Danø K; Blasi F
J Biol Chem; 1988 Feb; 263(5):2358-63. PubMed ID: 2828365
[TBL] [Abstract][Full Text] [Related]
20. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.
Rabbani SA; Mazar AP; Bernier SM; Haq M; Bolivar I; Henkin J; Goltzman D
J Biol Chem; 1992 Jul; 267(20):14151-6. PubMed ID: 1321137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
